Trial intelligence / Profile preview

Omeprazole 20 mg vs 10 mg vs placebo once daily for 4-week treatment of non-erosive reflux disease

jRCT2080220395Phase 3

Sponsor
AstraZeneca
Start
May 2007
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial of omeprazole in Non-erosive Gastroesophageal Reflux Disease (NERD) (3 arms), sponsored by AstraZeneca.

02

Drugs

omeprazole
03

Conditions

Non-erosive Gastroesophageal Reflux Disease (NERD)

Beyond the preview

Go deeper on jRCT2080220395.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT2080220395.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call